{"id":154054,"date":"2026-11-17T09:03:21","date_gmt":"2026-11-17T00:03:21","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4888-20261117-01_wp_financial_summary\/"},"modified":"2026-11-17T09:03:21","modified_gmt":"2026-11-17T00:03:21","slug":"4888-20261117-01_wp_financial_summary","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/","title":{"rendered":"2nd Quarter Financial Results Presentation"},"content":{"rendered":"<p>Interim sales decreased 12.5% year-over-year to 175 million yen. Selling, general and administrative expenses increased mainly due to production transfer-related costs, resulting in an operating loss of -498 million yen, ordinary loss of -467 million yen, and interim net loss of -469 million yen. Full-year outlook unchanged for now: sales 1,038 million yen, operating loss -696 million yen, interim net loss -628 million yen. Capital policy explained to invest approximately 4.2 billion yen into six growth themes.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"Stella Pharma Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4888-20261117-01.pdf","jir_short_summary":"Interim sales decreased 12.5% year-over-year to 175 million yen. Selling, general and administrative expenses increased mainly due to production transfer-related costs, resulting in an operating loss of -498 million yen, ordinary loss of -467 million yen, and interim net loss of -469 million yen. Full-year outlook unchanged for now: sales 1,038 million yen, operating loss -696 million yen, interim net loss -628 million yen. Capital policy explained to invest approximately 4.2 billion yen into six growth themes.","jir_summary":"### Performance Overview\nIn the interim period, sales decreased 12.5% year-over-year. Although the gross profit margin was maintained at the same level as the previous period, SG&A expenses increased significantly mainly due to higher production transfer-related costs. As a result, operating income, ordinary income and interim net income were in deficit. Subsidy income of 53 million yen was recorded as non-operating income, partially offsetting the ordinary loss and net loss.\n\n### Full-Year Outlook and Capital Policy\nFor the full year, the company forecasts sales of 1,038 million yen, operating loss of -696 million yen, ordinary loss of -625 million yen, and interim net loss of -628 million yen. As a medium-term growth strategy, approximately 4.2 billion yen will be invested across six growth themes (expansion of new businesses, broadened indications, overseas expansion, market development, talent acquisition, etc.), promoting reconstruction of the supply base and regional deployment centered on the BNCT business.","jir_financial_highlights":"Sales: 175 (YoY -25)\nSales: 323 (YoY Unknown)\nGross Profit: 145 (YoY -20)\nSG&A: 643 (YoY +178)\nOperating Income: -498 (YoY Unknown)\nOrdinary Income: -467 (YoY Unknown)\nNet Income Attributable to Owners of Parent (Interim): -469 (YoY Unknown)","jir_category":"","jir_hashtags":"#StellaPharma, #InterimResults, #BNCT, #IndicationExpansion, #HainanIsland, #ProductionTransfer","jir_key_figures":"Sales: 175 million yen (YoY -12.5%), 2Q\nSG&A: 643.6 million yen, YoY +178.9 million yen\nOperating Income: -498 million yen\nInterim Net Income: -469 million yen\nSubsidy Income: 53 million yen (recorded as non-operating income)","jir_meta_title":"Stella Pharma Corporation Q2 Financial Results | Sales 175 million yen, widening losses","jir_meta_description":"Presentation of Stella Pharma Corporation's Q2 financial results: sales trends, causes of increased SG&A, full-year outlook and capital policy, and growth strategy for the BNCT business.","jir_og_title":"Stella Pharma Corporation Q2 Financial Results | Sales 175 million yen, losses widen","jir_og_description":"Summary of interim performance, full-year outlook and capital policy. Also covers expansion in the BNCT field and progress on Hainan Island deployment.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-154054","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>2nd Quarter Financial Results Presentation - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/\",\"name\":\"2nd Quarter Financial Results Presentation - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-17T00:03:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2nd Quarter Financial Results Presentation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2nd Quarter Financial Results Presentation - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/","url":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/","name":"2nd Quarter Financial Results Presentation - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-17T00:03:21+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4888\/ir\/4888-20261117-01_wp_financial_summary\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"2nd Quarter Financial Results Presentation"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59263","title":"STELLA PHARMA CORPORATION","ticker":"4888"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=154054"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154054\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=154054"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=154054"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=154054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}